

MARKET REPORT



Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs

Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs

Summary

Gastric cancer is the fifth most common cancer globally, and due to its indolent nature remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The gastric cancer market is undergoing a gradual change, from a focus on generic chemotherapy regimens to complex treatment landscape based on targeted therapies. Recently the market has witnessed the approval of efficacious therapies such as Cyramza, but this only benefits a small subset of patients. As the understanding of disease pathophysiology increases, new targets need to be identified and converted into improved therapeutic options. The current pipeline shows strong promise, as it shows a gradual shift from generic cytotoxic therapies to more diverse targeted therapies.

Scope

- What is the pathophysiology of gastric cancer?
- How is gastric cancer diagnosed?
- What are the current treatment options?
- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer patients?
- What implications will the increased focus on targeted therapies have on the future of gastric cancer treatment?
- What are the most promising first-in-class targets for gastric cancer?
- Will the current first-in-class targets have a broader therapeutic potential across the industry?
- How do deal frequency and value compare between target families and molecule types?
- How do licensing and co-development deals compare between first-in-class and non-first-in-class profiles?

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies
- Visualize the composition of the gastric cancer market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the gastric cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to

treating gastric cancer.

- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.

- Identify commercial opportunities in the gastric cancer deals landscape by analyzing trends in licensing and co-development deals and producing a list of gastric cancer therapies that are not yet involved in deals, and may be potential investment opportunities.

Additional Details

Publisher : GBI Research

Reference :

Number of Pages : 70

Report Format : PDF

Publisher Information :



GBI RESEARCH
GLOBAL BUSINESS INTELLIGENCE

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs [Published by GBI Research]

- 1 Table of Contents1 Table of Contents 21.1 List of Tables 31.2 List of Figures 32 Executive Summary 42.1 Significant Unmet Needs in the Gastric Cancer Market 42.2 High Proportion of First-in-Class Innovation Offers Promise in Gastric Cancer 42.3 Deal Activity Varies with First-in-Class Status 43 The Case for Innovation 53.1 Growing Opportunities for Biologic Products 63.2 Diversification of Molecular Targets 63.3 Innovative First-in-Class Product Development Remains Attractive 63.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 73.5 Sustained Innovation 73.6 GBI Research Report Guidance 84 Clinical and Commercial Landscape 94.1 Disease Overview 94.2 Disease Symptoms 94.3 Epidemiology and Etiology 94.4 Pathophysiology 94.4.1 Helicobacter Pylori 104.4.2 Oncogenes 104.4.3 Tumor Suppressor Genes 104.4.4 Cell Adhesion Molecules and Metastasis-Related Genes 104.4.5 Cell Cycle Regulators 104.4.6 Microsatellite and Chromosomal Instability 104.4.7 Growth Factor and Cytokines 114.5 Diagnosis and Staging 114.6 Classification 124.6.1 Intestinal Subtype 124.6.2 Diffuse Subtype 124.7 Prognosis 124.8 Treatment Options 134.8.1 Surgery 134.8.2 First-Line Therapy 134.8.3 Second-Line Therapy 164.9 Overview of Marketed Products in Gastric Cancer 174.9.1 Molecule Type and Target Analysis 174.9.2 Innovative Products in Gastric Cancer Market 194.9.3 Unmet Needs 195 Assessment of Pipeline Product Innovation 205.1 Gastric Cancer Pipeline by Molecule Type, Phase and Therapeutic Target 205.2 Comparative Distribution of Programs between the Gastric Cancer Market and Pipeline by Therapeutic Target Family 245.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets 246 Signaling Network, Disease Causation and Innovation Alignment 316.1 Complexity of Signaling Networks in Oncology 316.2 Signaling Pathways and First-in-Class Molecular Target Integration 326.3 First-in-Class Matrix Assessment 327 First-in-Class Target Evaluation 357.1 Pipeline Programs Targeting HER 3 357.2 Pipeline Programs Targeting Ataxia Telangiectasia Mutated 377.3 Pipeline Programs Targeting L1 Cell Adhesion Molecule 387.4 Pipeline Programs Targeting Akt 1, 2 and 3 407.5 Pipeline Programs Targeting Fibroblast Growth Factor receptor 3 447.6 Pipeline Programs Targeting 3-Phosphoinositide-Dependent Protein Kinase 1 467.7 Conclusion 478 Deals and Strategic Consolidation 488.1 Industry-Wide First-in-Class Deals 488.2 Licensing Deals 498.2.1 Licensing Deals by Molecule Type 518.2.2 Licensing Deals by Molecular Target 528.2.3 Conclusion 538.3 Co-development Deals 548.3.1 Co-development Deals by Molecule Type 578.3.2 Co-development Deals by Molecular Target 578.3.3 Conclusion 588.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals 599 Appendix 629.1 References 629.2 Abbreviations 669.3 Research Methodology 689.4 Secondary Research 699.4.1 Marketed Product Heatmaps and Treatment Algorithm 699.4.2 Pipeline Analysis 699.4.3 First-in-Class Matrix Assessment 699.4.4 First-in-Class Target Profiles 709.4.5 Licensing and Co-Development Deals 709.5 Contact Us 709.6 Disclaimer 70

List Of Tables in Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs [Published by GBI Research]

1.1 List of Tables

Table 1: Gastric Cancer, Tumor, Node and Metastasis Staging 12

Table 2: Gastric Cancer, Key Features and Pipeline Activity of HER 3 36

Table 3: Gastric Cancer, Key Features and Pipeline Activity of ATM 38

Table 4: Gastric Cancer, Key Features and Pipeline Activity of L1CAM 39

Table 5: Frequency of Mutations in Components in Akt Proteins, by Cancer Type 41

Table 6: Gastric Cancer, Key Features and Pipeline Activity of AKT 1 42

Table 7: Gastric Cancer, Key Features and Pipeline Activity of AKT 2 42

Table 8: Gastric Cancer, Key Features and Pipeline Activity of AKT 3 43

Table 9: Gastric Cancer, Key Features and Pipeline Activity of FGFR-3 45

Table 10: Gastric Cancer, Key Features and Pipeline Activity of PDPK1 46

Table 11: List of Abbreviations 66

List Of Figures, Charts and Diagrams in Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs [Published by GBI Research]

1.2 List of Figures

Figure 1: Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Products Approvals (%), 1987–2012 5

Figure 2: First-in-Class and Non-First-in-Class Products, Sales Performance After Marketing Approval (\$m) 7

Figure 3: Gastric Cancer, Heatmap for First-Line Marketed Products 15

Figure 4: Gastric Cancer, Heatmap for Second-Line Therapy Marketed Products 17

Figure 5: Gastric Cancer, Overview of Marketed Products 18

Figure 6: Gastric Cancer , Overview of Pipeline Products 21

Figure 7: Gastric Cancer, Molecular Targets in Pipeline 23

Figure 8: Gastric Cancer, Pipeline by Molecular Targets and Stage of Development 24

Figure 9: Gastric Cancer, Molecular Target Family Comparison, Pipeline and Marketed Products 24

Figure 10: Gastric Cancer, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets 26

Figure 11: Gastric Cancer, Percentage of First-in-Class Products in Pipeline by Molecular Target Family (%) 27

Figure 12: Gastric Cancer, Percentage of First-in-Class Products in Pipeline by Stage of Development (%) 27

Figure 13: Gastric Cancer, First-in-Class Products in Pipeline (Part 1) 28

Figure 14: Gastric Cancer, First-in-Class Products in Pipeline (Part 2) 29

Figure 15: Gastric Cancer, First-in-Class Products in Pipeline (Part 3) 30

Figure 16: Gastric Cancer, Target Matrix Assessment (Part 1) 33

Figure 17: Gastric Cancer, Target Matrix Assessment (Part 2) 34

Figure 18: Gastric Cancer, Programs Targeting HER 3 36

Figure 19: Gastric Cancer, Programs Targeting ATM 38

Figure 20: Gastric Cancer, Programs Targeting L1CAM 39

Figure 21: Gastric Cancer, Programs Targeting AKT 1 43

Figure 22: Gastric Cancer, Programs Targeting AKT 2 43

Figure 23: Gastric Cancer, Programs Targeting AKT 3 43

Figure 24: Gastric Cancer, Programs Targeting FGFR 3 46

- Figure 25: Gastric Cancer, Programs Targeting PDPK1 46
- Figure 26: Gastric Cancer, Deals by Stage of Development, 2006–2014 48
- Figure 27: Gastric Cancer, Licensing Deal Values by Stage of Development (\$m), 2006–2014 49
- Figure 28: Gastric Cancer, Licensing Deal Value, 2006–2015 50
- Figure 29: Gastric Cancer, Licensing Deals by Year, 2006–2015 50
- Figure 30: Gastric Cancer, Licensing Deals by Stage of Development, 2006–2015 51
- Figure 31: Gastric Cancer, Licensing Deal Value by Stage of Development and Molecule Type, 2006–2015 52
- Figure 32: Gastric Cancer, Licensing Deal Value by Molecular Target, 2006–2015 53
- Figure 33: Gastric Cancer, Summary of Licensing Deals, 2006–2015 54
- Figure 34: Gastric Cancer, Co-development Deal Value, 2006–2015 55
- Figure 35: Gastric Cancer, Co-development Deals by Year, 2006–2015 55
- Figure 36: Gastric Cancer, Co-development Deals by Stage of Development, 2006–2015 56
- Figure 37: Gastric Cancer, Co-development by Stage of Development and Molecule Type, 2006–2015 57
- Figure 38: Gastric Cancer, Co-development by Stage of Development and Molecular Target, 2006–2015 58
- Figure 39: Gastric Cancer, Summary of Co-development Deals, 2006–2015 59
- Figure 40: Gastric Cancer, First-in-Class Therapies Not Involved in Deals (Part 1) 60
- Figure 41: Gastric Cancer, First-in-Class Therapies Not Involved in Deals (Part 2) 61

How to Buy...

Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs [Published by GBI Research]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/25768>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$6995** | Single User Price
- \$13990** | Site License Price
- \$20985** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.